Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Infographics: things to know about AMR

FACT: Antimicrobial resistance (AMR): when microbes, like bacteria, evolve to survive exposure to antimicrobial medicines, such as antibiotics, used for treatment or prevention (prophylaxis). This makes antimicrobials less effective and infections more difficult to treat. MSF
AMR: One of the most significant global public health threats of our time. By 2050, AMR is estimated to contribute to 8.2 million deaths worldwide.. MSF
FACT: Humanitarian settings compound the AMR crisis. Natural disasters. Displacement. Overcrowded places. Conflict. Collapsed health systems. MSF
FACT: People in low- and middle-income countries experience the highest rates of AMR globally, with limited access to diagnostic tools and microbiology capacities to identify AMR and medicines to treat AMR. MSF
MSF address AMR through dedicated prevention, detection, and response efforts: +20 countries, +50 projects. MSF's AMR response package includes infection prevention and control, antibiotic stewardship, and providing access to microbiology lab-based diagnostics and surveillance. MSF
CONCRETE ACTION IS NEEDED. Ensure equitable access to existing diagnostic tools, microbiology capacities, legacy and new lifesaving antibiotics, AND increase research and development for low-resource and humanitarian settings, where it is most needed. MSF

Read, watch, share

Medicines a patient brought to his consultation in Ahmad Shah Baba hospital in Kabul, to show a doctor which drugs he needs. Photograph by Doris Burtscher Photograph by Doris Burtscher
Interview
Interview |
09 March 2017
Antimicrobial resistance

MSF takes on antibiotic resistance

6 min
Antibiotic Resistance Running Out Options Photograph by Vivian Lee
Press release
Press release |
27 February 2017
Antimicrobial resistance

MSF response to WHO antibiotic-resistant "priority pathogens" list

2 min
Video
Video |
24 February 2017
Antimicrobial resistance

Killer diseases - Antimicrobial resistance

Drug-resistant patient showing daily drug dose Photograph by Sami Siva
Press release
Press release |
21 September 2016
Antimicrobial resistance

MSF Statement on Political Declaration of the United Nations General Assembly High-Level Meeting on Antimicrobial Resistance

3 min
Statement |
06 June 2016
Antimicrobial resistance

MSF Remarks on Launch of O’Neill Report on Antimicrobial Resistance

6 min
Staff at the Epworth clinic pharmacy preparing medication to be collected by patient. Photograph by Ikram N'gadi Photograph by Ikram N'gadi
Press release
Press release |
27 May 2016
Antimicrobial resistance
G7Japan

No guts from G7 leaders to tackle one of the biggest threats to global health

Statement |
23 May 2016
Antimicrobial resistance

WHO 69th World Health Assembly: Agenda item 14.4 - Global Action Plan on Antimicrobial Resistance

National TB Centre, Abovian, Armenia February 2010. The injections, pills and powders DR TB patients must take are toxic antibiotics, the most recent of which was developed 40 years ago. Most patients suffer side effects that can sometimes cause more discomfort than the disease. Photograph by Bruno De Cock
Press release
Press release |
18 May 2016
Antimicrobial resistance
United Kingdom

MSF response to O’Neill report on antimicrobial resistance

  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury